Loading data for ZBIO — first visit, this takes a few seconds.
Zenas BioPharma, Inc.
26.76 -0.79 (-2.87%)
26.76 +0.00%
- Market Cap
- $1.74B
- Volume
- 441K
- Dividend yield
- n/a
- Next earnings date
- Nov 12, 2026
Zenas BioPharma, Inc. (ZBIO) Stock Price, Analysis & Data
You're seeing the free overview
Create a free account to open financials, options, forecasts and the rest of this ticker.
Intrinsic value
See plans →Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $1.00M | n/a | n/a |
| EPS | -$1.77 | -$1.02 | -41.60% |
Metrics
- Bid
- 19.68
- Market Cap
- 1.74B
- Net Income (ttm)
- -484M
- -1.02
- -9.63
- n/a
- -5.74
- P/B (ttm)
- 6.86
- P/S (ttm)
- 1744.13
- Earnings Date
- Nov 12, 2026
- Ask
- 33.61
- Volume
- 440,627
- Avg. Volume (20D)
- 770,206
- Open
- 27.30
- Previous Close
- 27.55
- Day's Range
- 26.18 - 27.33
- 52-Week Range
- 13.50 - 44.60
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Zenas BioPharma, Inc.
View profile →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Industry Biotechnology
Sector Healthcare
IPO Date Sep 13, 2024
Employees 167
Stock Exchange NasdaqGS
Ticker Symbol ZBIO
Website https://zenasbio.com